Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued
Reference number: GID-TA10177
Following on from information provided to NICE by the company in June 2017, the appraisal of Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.